arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Phathom Pharmaceuticals, Inc.

PHAT Health Care Biotechnology: Pharmaceutical Preparations
$5.74
▼ -18.4% Today
as of Oct 23, 16:51 ET
Last 30 days -33.87% Sep 14 → Oct 23
$5.50 $6.36 $7.21 $8.06 $8.92 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$6.72
High
$6.76
Low
$5.02
Volume
$5M
Avg Vol
$1M
Mkt Cap
$551M
P/E (TTM)
—
Beta
—
52w High
$18.31
52w Low
$5.02
Div Yield
—
Shares Out
$80M

Recent Press Releases & News last 60 days · 11 items

Oct 23 · 17:45 Stocktwits
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
Oct 23 · 09:39 MT Newswires
Phathom Pharmaceuticals Faces Legal Challenge Over VOQUEZNA Exclusivity
Oct 23 · 08:00 PR GlobeNewswire
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
▸ Show all 11 press releases & news Free account →

PHAT earnings at a glance

Phathom Pharmaceuticals, Inc. (PHAT) is scheduled to report earnings on Thursday, October 29, 2026 — in 5 days. Analysts expect earnings per share of -$0.01, compared with -$0.28 in the same quarter last year (+96%). The options market is pricing a move of about ±70.1% after the report, a range of roughly $1.71 to $9.77 from today's $5.74. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±11.5% on average; after the most recent report on Jul 30, 2026 it moved -22.4%. That means options currently expect more movement than PHAT has typically delivered. PHAT beat the consensus EPS estimate in 5 of its last 6 reported quarters. Implied volatility is currently 6%. The share price of $5.74 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$5.02
$18
5% of range
Avg surprise (last 6)
+16.7%
Avg reaction (last 6)
-5.4%
33% positive
Latest IV / EM
594%
EM ±70.1% · $8 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.56$-1.19$-0.82$-0.45$-0.08 Actual $-0.89Actual $-0.84Actual $-0.76Actual $-1.42Actual $-1.56Actual $-1.32Actual $-1.15Est $-1.16Actual $-0.90Est $-0.86Actual $-0.28Est $-0.40Actual $-0.16Est $-0.20Actual $-0.25Est $-0.27Actual $-0.08Est $-0.15 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$-94M$-51M$-8M$35M$78M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 30, 2026Jun/2026 $-0.08 $-0.15 +46.7% +83.3% -22.4% earnings
Thu Apr 30, 20268K 2026-04-30 $-0.25 $-0.27 +7.4% — -4.9% earnings
Thu Feb 26, 20268K 2026-02-26 $-0.16 $-0.20 +20.0% — +10.1% earnings
Thu Oct 30, 2025Sep/2025 $-0.28 $-0.40 +30.0% — -1.6% earnings
Thu Aug 7, 2025Jun/2025 $-0.90 $-0.86 -4.7% — +8.3% earnings
Thu May 1, 2025Mar/2025 $-1.15 $-1.16 +0.9% — -21.7% earnings
Mon Sep 30, 2024Sep 2024 $-1.32 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.56 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.42 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.76 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.84 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.89 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Oct 29, 2026Sep/2026OTHER -$0.01-$0.28 +96.4%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$74M$58M—$50M$40M$29M—$16M
Cost of revenue$15M$12M—$6M$5M$4M—$2M
Gross profit$59M$46M—$43M$34M$25M—$14M
Operating income$-4M$-15M—$-15M$-60M$-79M—$-71M
Net income$-18M$-30M—$-30M$-76M$-94M—$-86M
EPS (diluted)$-0.21$-0.37—$-0.41$-1.05$-1.31—$-1.32

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$182M$181M$130M$135M$150M$212M$297M$335M
Inventory$8M$7M$6M$4M$3M$3M$3M$3M
Total current assets$296M$277M$229M$208M$219M$265M$360M$374M
Total assets$327M$305M$259M$240M$250M$294M$378M$387M
Long-term debt$165M$164M$209M$207M$205M$203M$201M$176M
Total liabilities$671M$642M$697M$663M$656M$633M$632M$574M
Total equity$-344M$-337M$-438M$-423M$-406M$-338M$-254M$-187M

Implied volatility — last 90 days

47%293%540%787%1033% Jun 10 — IV 78% · EM ±9.2%Jun 11 — IV 225% · EM ±24.8%Jun 12 — IV 160% · EM ±16.4%Jun 17 — IV 1034% · EM ±43.2%Jun 19 — IV 143% · EM ±31.7%Jun 22 — IV 56% · EM ±11.7%Jun 23 — IV 47% · EM ±9.7%Jun 24 — IV 56% · EM ±11.3%Jun 25 — IV 59% · EM ±11.6%Jun 26 — IV 66% · EM ±12.6%Jun 29 — IV 63% · EM ±11.2%Jun 30 — IV 64% · EM ±11.1%Jul 01 — IV 54% · EM ±9.0%Jul 07 — IV 259% · EM ±34.2%Jul 08 — IV 344% · EM ±43.1%Jul 10 — IV 391% · EM ±43.2%Jul 20 — IV 142% · EM ±33.6%Jul 21 — IV 115% · EM ±26.7%Jul 22 — IV 98% · EM ±22.4%Jul 23 — IV 194% · EM ±43.5%Jul 24 — IV 167% · EM ±37.0%Jul 27 — IV 168% · EM ±35.1%Jul 28 — IV 114% · EM ±23.4%Jul 29 — IV 157% · EM ±31.4%Jul 30 — IV 144% · EM ±28.2%Jul 31 — IV 308% · EM ±58.9%Aug 03 — IV 99% · EM ±17.5%Aug 04 — IV 254% · EM ±43.8%Aug 05 — IV 175% · EM ±29.2%Aug 06 — IV 173% · EM ±28.0%Aug 07 — IV 178% · EM ±27.9%Aug 12 — IV 206% · EM ±25.8%Aug 13 — IV 175% · EM ±20.7%Aug 14 — IV 304% · EM ±33.6%Aug 17 — IV 239% · EM ±19.9%Aug 18 — IV 276% · EM ±20.0%Aug 24 — IV 174% · EM ±36.4%Aug 25 — IV 286% · EM ±58.5%Aug 26 — IV 184% · EM ±36.8%Aug 27 — IV 286% · EM ±55.9%Aug 31 — IV 295% · EM ±52.2%Sep 02 — IV 323% · EM ±54.0%Sep 04 — IV 74% · EM ±11.6%Sep 07 — IV 84% · EM ±11.6%Sep 08 — IV 165% · EM ±21.7%Sep 11 — IV 255% · EM ±28.2%Sep 21 — IV 161% · EM ±33.6%Sep 22 — IV 189% · EM ±38.7%Sep 23 — IV 100% · EM ±20.0%Sep 24 — IV 340% · EM ±66.5%Sep 25 — IV 193% · EM ±37.0%Sep 28 — IV 69% · EM ±12.2%Sep 29 — IV 67% · EM ±11.5%Sep 30 — IV 66% · EM ±11.0%Oct 01 — IV 131% · EM ±21.2%Oct 02 — IV 472% · EM ±73.7%Oct 06 — IV 550% · EM ±72.7%Oct 07 — IV 486% · EM ±60.9%Oct 08 — IV 594% · EM ±70.1%

Sector peers

CTMX
CytomX Therapeutics, Inc.
$556M $2.32-3.3%
STTK
Shattuck Labs, Inc.
$568M $5.49-1.6%
SGMT
Sagimet Biosciences Inc.
$577M $9.58-4.1%
CAPR
Capricor Therapeutics, Inc.
$520M $5.93+0.8%
OCS
Oculis Holding AG
$508M $7.90+0.4%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%

PHAT earnings FAQ

When is PHAT's next earnings date?

Phathom Pharmaceuticals, Inc. is expected to report on October 29, 2026.

What is PHAT's expected move for earnings?

Options currently price a move of about ±70.1%, or $4.03 per share either way from $5.74.

How does PHAT stock usually react to earnings?

Across the last 6 reports the average next-day move was ±11.5%, up 2 times and down 4 times.

What EPS are analysts expecting from Phathom Pharmaceuticals, Inc.?

The consensus estimate is -$0.01 per share, versus -$0.28 a year ago.

What is PHAT's implied volatility?

PHAT's at-the-money implied volatility is about 6% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in